VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

11025	Companies
241656	Keywords
170132	Articles
130105	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 08/25/2025 at 07:00, 1 year ago

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Valneva SE announces FDA's suspension of IXCHIQ® chikungunya vaccine license in the U.S. due to serious adverse events, despite reported cases consistent with clinical trials. Sales impact to be evaluated

FDA Valneva SE Chikungunya Vaccine License Suspension Serious Adverse Events
BRIEF

published on 08/19/2025 at 10:44, 1 year ago

First Berlin Maintains Buy Rating for Valneva Amid Strong Q2 Results

BUY Rating Q2 Results Valneva SE Lyme Disease Vaccine Chikungunya Vaccine
PRESS RELEASE

published on 08/19/2025 at 10:39, 1 year ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH has published a research update on Valneva SE, maintaining their BUY rating and EUR 8.10 price target, following better-than-expected Q2/25 results and positive outlook on vaccines

BUY Rating Research Update Q2 Results Valneva SE Vaccine Outlook
BRIEF

published on 08/18/2025 at 07:05, 1 year 1 month ago

Valneva's IXCHIQ® Vaccine Authorized in Canada for Ages 12 and Older

Health Canada Valneva Vaccine Authorisation Chikungunya
PRESS RELEASE

published on 08/18/2025 at 07:00, 1 year 1 month ago

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Valneva's Chikungunya Vaccine IXCHIQ® authorized in Canada for individuals aged 12 and older. Health Canada grants marketing authorization for disease prevention

Canada Health Valneva Vaccine Chikungunya
BRIEF

published on 08/12/2025 at 07:05, 1 year 1 month ago

Valneva's Half-Year 2025 Financial Report: Growth and Strategic Moves

Financial Results Strategic Partnerships Revenue Growth Cash Management Regulatory Updates
PRESS RELEASE

published on 08/12/2025 at 07:00, 1 year 1 month ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
Valneva SE reports €97.6 million revenues in H1 2025, confirms 2025 financial outlook. Highlights financial results, R&D progress, and commercial updates

Revenues Financial Results Valneva SE R&D Progress 2025 Outlook Commercial Updates
BRIEF

published on 08/07/2025 at 07:22, 1 year 1 month ago

Valneva Obtains FDA Lift of Ban on IXCHIQ®

FDA Valneva Chikungunya IXCHIQ® Vaccine Elderly People
PRESS RELEASE

published on 08/07/2025 at 07:17, 1 year 1 month ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
Valneva announces FDA's removal of recommended pause on Chikungunya Vaccine IXCHIQ® in elderly individuals and updates to the Prescribing Information, following EMA's recommendation. Updates reflect Serious Adverse Events and expanded Warnings and Precaution section

FDA Valneva Chikungunya Vaccine Prescribing Information Vaccine Updates
BRIEF

published on 07/28/2025 at 13:51, 1 year 1 month ago

Valneva SE: Positive Outlook Amid Chikungunya Concerns

Biotech Valneva SE Equity Research Chikungunya Vaccine Market

Accesswire

Published on 09/19/2026 at 00:55, 53 minutes ago

Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 1 hour 58 minutes ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 3 hours 48 minutes ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 5 hours 13 minutes ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 11 hours 18 minutes ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

View all ACCESSWIRE

EQS Group

Published on 09/18/2026 at 18:45, 7 hours 3 minutes ago

Holding(s) in Company
Published on 09/18/2026 at 18:44, 7 hours 4 minutes ago

EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 7 hours 35 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 7 hours 39 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:07, 7 hours 41 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS

Les Echos

Published on 09/18/2026 at 18:34, 7 hours 14 minutes ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 8 hours 3 minutes ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 8 hours 3 minutes ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 1 day 8 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 2 days 5 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE